The past three decades have borne witness to many advances in the understanding of the
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …

Nasopharyngeal carcinoma is characterised by distinct geographical distribution and is
particularly prevalent in east and southeast Asia. Epidemiological trends in the past decade …

Gemcitabine-cisplatin (GP) chemotherapy is the standard first-line systemic treatment for
recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double …

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the
nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these …

PURPOSE As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal
carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and …

Background Platinum-based concurrent chemoradiotherapy is the standard of care for
patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine …

Background Platinum-based doublet chemotherapy regimens, preferentially gemcitabine
plus cisplatin, are generally considered the first-line standard of care for patients with …

The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment
recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary …

Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M
NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC …

Purpose: To identify MRI-based radiomics as prognostic factors in patients with advanced
nasopharyngeal carcinoma (NPC). Experimental Design: One-hundred and eighteen …